» Articles » PMID: 18304973

Overtreatment with Inhaled Corticosteroids and Diagnostic Problems in Primary Care Patients, an Exploratory Study

Overview
Journal Fam Pract
Specialty Public Health
Date 2008 Feb 29
PMID 18304973
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Underdiagnosis and undertreatment of patients with asthma or chronic obstructive pulmonary disease are widely discussed in the literature. Not much is known about the possible overdiagnosis and consequently the overtreatment with inhaled corticosteroids (ICS). Aim. This study investigates how often ICS are prescribed without a proper indication and how big the diagnostic problem is caused by inappropriate prescription and use of ICS.

Methods: All patients referred to a primary care diagnostic centre during 6 months who used ICS without a clear indication were included. Their GPs were questioned about the reasons for prescribing ICS. If still no diagnosis could be assessed, GPs were advised to stop ICS and renew spirometry after a steroid-free period of at least 3 months. After 1 year, the use of ICS was evaluated and the diagnoses were reassessed.

Results: Of all referred patients (2271), 1171 used ICS, 505 (30%) without a clear indication. After 1 year, final results showed that 11% of all patients originally using ICS had no indication to use ICS and had successfully ceased using this mediation. For 15%, the reasons for using ICS remained unclear.

Conclusions: Overtreatment with ICS in primary care seems to be considerable, which falsely labels patients as asthmatic and which generates unnecessary costs and possible side effects. The awareness of GPs of the need for proper diagnostic testing before prescribing ICS needs to be improved. Overtreatment with ICS in primary care patients can be diminished by systematically supporting the GP in the diagnostic procedures and decision making.

Citing Articles

Long-term impact of COVID-19 hospitalisation among individuals with pre-existing airway diseases in the UK: a multicentre, longitudinal cohort study - PHOSP-COVID.

Elneima O, Hurst J, Echevarria C, Quint J, Walker S, Siddiqui S ERJ Open Res. 2024; 10(4).

PMID: 39010888 PMC: 11247371. DOI: 10.1183/23120541.00982-2023.


Sputum microbe community alterations induced by long-term inhaled corticosteroid use are associated with airway function in chronic obstructive pulmonary disease patients based on metagenomic next-generation sequencing (mNGS).

Yue Y, Zhang B, He Z, Zheng Y, Wang X, Zhang Q Front Pharmacol. 2024; 15:1323613.

PMID: 38915461 PMC: 11194361. DOI: 10.3389/fphar.2024.1323613.


Exploring the appropriateness of prescribing practice of inhaled pharmacotherapy among Aboriginal Australians in the Top End Northern Territory of Australia: a retrospective cohort study.

Heraganahally S, Howarth T, Issac S, Lloyd A, J Ravichandran S, Abeyaratne A BMJ Open Respir Res. 2023; 10(1).

PMID: 36878611 PMC: 9990608. DOI: 10.1136/bmjresp-2022-001508.


Practical Recommendations for a Selection of Inhaled Corticosteroids in COPD: A Composite ICO Chart.

Oishi K, Matsunaga K, Yamamoto T, Matsuda K, Murata Y, Hirano T Biomolecules. 2023; 13(2).

PMID: 36830583 PMC: 9953425. DOI: 10.3390/biom13020213.


Inhaled Corticosteroids and the Lung Microbiome in COPD.

Keir H, Contoli M, Chalmers J Biomedicines. 2021; 9(10).

PMID: 34680429 PMC: 8533282. DOI: 10.3390/biomedicines9101312.